# **Special Issue**

# Hybrid Agents for Multimodal Imaging

### Message from the Guest Editors

The journal Pharmaceuticals is planning to publish a Special Issue, Hybrid Agents for Multimodal Imaging, and I am cordially inviting you to contribute an article to this volume, describing your latest research and, of course, reviews are welcome as well. The use of imaging to visualize and characterize a wide variety of diseases is deeply embedded in routine clinical practice. In addition to conventional imaging, the combination of imaging modalities is of increasing relevance and an increasing number of complementary combinations are being used to the benefit of patients. For this reason, a growing field of research has been focusing for several vears on the development of combined or combinable contrast agents that can be detected using multiple imaging modalities, thus allowing a complementary gain of information. The goal of this Special Issue is to gather the latest developments in this area of hybrid imaging agent development for multimodal imaging to provide the most complete coverage of this exciting and forward-looking area of research.

### **Guest Editors**

#### Prof. Dr. Carmen Wängler

Biomedical Chemistry, Clinic of Radiology and Nuclear Medicine, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany

### Dr. Ralph Hübner

Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

### Deadline for manuscript submissions

closed (25 February 2022)



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.3 CiteScore 6.1 Indexed in PubMed



mdpi.com/si/77182

Pharmaceuticals MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.3 CiteScore 6.1 Indexed in PubMed





# About the Journal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

### Editor-in-Chief

#### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

### **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Pharmaceutical Science)